JP2020533296A - 薬物誘発性ジスキネジアを治療するためのプリドピジン - Google Patents

薬物誘発性ジスキネジアを治療するためのプリドピジン Download PDF

Info

Publication number
JP2020533296A
JP2020533296A JP2020513603A JP2020513603A JP2020533296A JP 2020533296 A JP2020533296 A JP 2020533296A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020513603 A JP2020513603 A JP 2020513603A JP 2020533296 A JP2020533296 A JP 2020533296A
Authority
JP
Japan
Prior art keywords
day
predopidine
administered
levodopa
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533296A5 (enExample
Inventor
ゲヴァ、ミカル
オーバック、アリック
ヘイデン、マイケル
Original Assignee
プリレニア ニューロセラピューティクス リミテッド
プリレニア ニューロセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリレニア ニューロセラピューティクス リミテッド, プリレニア ニューロセラピューティクス リミテッド filed Critical プリレニア ニューロセラピューティクス リミテッド
Publication of JP2020533296A publication Critical patent/JP2020533296A/ja
Publication of JP2020533296A5 publication Critical patent/JP2020533296A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020513603A 2017-09-08 2018-08-30 薬物誘発性ジスキネジアを治療するためのプリドピジン Pending JP2020533296A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US62/556,314 2017-09-08
US201862649184P 2018-03-28 2018-03-28
US62/649,184 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
JP2020533296A true JP2020533296A (ja) 2020-11-19
JP2020533296A5 JP2020533296A5 (enExample) 2021-03-04

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513603A Pending JP2020533296A (ja) 2017-09-08 2018-08-30 薬物誘発性ジスキネジアを治療するためのプリドピジン

Country Status (10)

Country Link
US (2) US20190231768A1 (enExample)
EP (1) EP3678664A1 (enExample)
JP (1) JP2020533296A (enExample)
CN (1) CN111343982A (enExample)
AU (1) AU2018329628B2 (enExample)
BR (1) BR112020004622A2 (enExample)
CA (1) CA3075020C (enExample)
IL (1) IL273044A (enExample)
MX (1) MX383462B (enExample)
WO (1) WO2019050775A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
KR20250021199A (ko) 2023-08-03 2025-02-12 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US9139525B2 (en) 2007-04-12 2015-09-22 Teva Pharmaceuticals International Gmbh N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
EP2170327B1 (en) * 2007-06-18 2014-10-22 A.Carlsson Research AB Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2012002863A1 (en) 2010-07-02 2012-01-05 Aktiebolaget Skf Mechanical component and method for surface hardening
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
JP6189299B2 (ja) 2011-09-07 2017-08-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジン塩酸塩の新規な多形形態
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
DK3096759T3 (da) 2014-01-22 2022-05-09 Prilenia Neurotherapeutics Ltd Pridopidinformuleringer med modificeret frigivelse
WO2015138130A1 (en) 2014-03-10 2015-09-17 Applied Materials, Inc. Pixel blending for multiple charged-particle beam lithography
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
PL3570940T3 (pl) 2017-01-20 2024-06-17 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x
LT4154882T (lt) 2017-08-14 2025-11-25 Amiotrofinės lateralinės sklerozės gydymas pridopidinu
CA3073568A1 (en) * 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 698, JPN6021006840, 2013, pages 278 - 285, ISSN: 0004530600 *

Also Published As

Publication number Publication date
WO2019050775A1 (en) 2019-03-14
US20190350914A1 (en) 2019-11-21
AU2018329628B2 (en) 2021-04-22
IL273044A (en) 2020-04-30
CA3075020A1 (en) 2019-03-14
BR112020004622A2 (pt) 2020-09-24
US11000519B2 (en) 2021-05-11
EP3678664A1 (en) 2020-07-15
CA3075020C (en) 2021-12-07
MX2020002645A (es) 2021-06-10
MX383462B (es) 2025-03-14
CN111343982A (zh) 2020-06-26
AU2018329628A1 (en) 2020-04-16
US20190231768A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
US11000519B2 (en) Pridopidine for treating drug induced dyskinesias
US12409176B2 (en) Methods of treating acute depression
Baldessarini et al. Pharmacotherapy of psychosis and mania
US12478623B2 (en) Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
EP2900226A2 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
WO2004030633A2 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
KR20120101456A (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
US11135211B2 (en) Pimavanserin for treating impulse control disorder
JP6634445B2 (ja) ブスピロン代謝産物の使用
US20110034565A1 (en) Psycho-pharmaceuticals
CN113453683A (zh) 运动障碍的治疗
US20240197756A1 (en) Methods of treatment with neuroactive steroids
WO2020110128A1 (en) Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US12036213B2 (en) Pridopidine for treating drug induced dyskinesias
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response Patterns
WO2025154076A1 (en) Method of prolonging the survival of a subject with als

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210125

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210125

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210622

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211020

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221129

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230110

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230207

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20230207

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607